Patients with HIV receiving antiretroviral treatment have a higher risk of non-Hodgkin's lymphoma with HBV and HCV coinfection.
The FDA issues a warning about the risk of hepatitis B virus reactivation among patients taking direct-acting antivirals to treat hepatitis C infections.
Shortening the duration of HCV therapy from 12 weeks to 3 weeks could substantially reduce the cost of treatment.
In patients with Hepatitis C, Oral treatment with sofosbuvir plus ribavirin is preferred over interferon based triple therapy.
HCVcAg assays with signal amplification have the potential to replace NAT in settings with high HCV prevalence.
A new hepatology rotation increased the mean comfort level for managing several liver diseases.
In a study, 24% of confiscated drug snorting straws tested positive for human blood.
Patients previously treated for HCC have a high risk of tumor recurrence in the long term.
The combination drug treats 6 strains of chronic hepatitis C.
Patients with hepatitis C who had a multidisciplinary team during treatment had improved outcomes.
The number of deaths associated with hepatitis C is higher than the total number of deaths resulting from 60 other infectious diseases.
Direct-acting antivirals pose challenges in patients with hepatitis C and prior hepatocellular carcinoma
Treatment guidelines must expand to focus on patients co-infected with both HCV and HIV.
Patients with HCV/HIV coinfections had a much higher risk of HCV recurrence.
Education of high risk populations and regular testing are crucial steps clinicians can take to stem the spread of hepatitis C infection.
The organization encourages dialysis providers to improve current infection control practices.
Zepatier has been approved by the FDA to treat hepatitis C virus genotypes 1 and 4 infections in adult patients.
Fewer than 20% of surveyed nurses report total adherence to the standard precautions meant to prevent bloodborne pathogen transmission.
Only 8.3% of eligible patients at 14 health centers were screened for hepatitis C based on guidelines presented in 2013.
Hepatitis C drugs Viekira Pak and Technivie have been recently linked to serious liver damage in patients with advanced liver disease, said the FDA.
Statin use in co-infected patients showed a slowed progression of liver disease, according to a study conducted at the Johns Hopkins Moore Clinic for HIV Care.
Viekira Pak is indicated for chronic hepatitis C virus (HCV) genotype 1 infection, with or without ribavirin.
The FDA approved Technivie (ombitasvir, paritaprevir, ritonavir) for chronic hepatitis C gentotype 4 infection.
The combinations of ledipasvir plus sofosbuvir and daclatasvir plus sofosbuvir may effectively treat HIV, HCV coinfection.
Very few cases of hepatitis C meet the CDC's criteria for reporting.
High hepatitis C treatment costs with interferon-free regimens and ethical questions about re-treatment and resource allocation remain.
Viekirax plus Exviera without ribavirin was effective in patients with genotype 1b chronic hepatitis C virus infection and compensated liver cirrhosis.
The antihistamine chlorcyclizine HCl, which costs 50 cents per pill, may be able to treat hepatitis C.
Ledipasvir and sofosbuvir with or without ribavirin is effective and safe for treating chronic genotype 1 hepatitis C virus infections.